Butyrate does not protect against inflammation-induced loss of epithelial barrier function and cytokine production in primary cell monolayers from patients with ulcerative colitis.
J Crohns Colitis. 2019 Mar 28;:
Authors: Vancamelbeke M, Laeremans T, Vanhove W, Arnauts K, Ramalho AS, Farré R, Cleynen I, Ferrante M, Vermeire S
BACKGROUND AND AIMS: In vitro studies utilizing immortalised cancer cell lines showed that butyrate has an overall positive effect on epithelial barrier integrity, but the physiological relevance of cancer cell lines is limited. We developed epithelial monolayers from human tissue samples of patients with ulcerative colitis (UC) to assess the effect of butyrate on epithelial barrier function.
METHODS: A protocol to establish monolayers from primary epithelial cells of UC patients (n=10) and non-UC controls (n=10) was optimized. The monolayers were treated with 8mM sodium butyrate TNF and IFN for 48 hours. Changes in trans-epithelial electrical resistance were monitored. Barrier gene expression levels were measured. Inflammatory proteins in the supernatant of the cells were quantified with OLINK.
RESULTS: We demonstrated that primary monolayer cultures can be grown within one week of culture with robust resistance values and polarised tight junction expression. Butyrate treatment of the cultures increased resistance but was detrimental in combination with TNF and IFN. The combined treatment further induced even higher IL8 mRNA and inflammatory protein secretion than for the inflammatory mediators alone. The observed effects were similar in cultures from patients and non-UC controls suggesting that there were no patient-specific responses responsible for these findings.
CONCLUSIONS: We found that butyrate does not protect against inflammation-induced barrier dysfunction and even worsens its effects in primary epithelial monolayers of UC patients and controls. The basic mechanisms of butyrate should therefore be reconsidered in future studies, in particular in patients with active inflammation and pre-existing barrier defects as is known for UC.
PMID: 30919886 [PubMed – as supplied by publisher]